Deupirfenidone & IPF: New Hope for Lung Decline
- A recent phase 2B trial suggests that deupirfenidone, a novel molecular variant, could offer a new approach to managing idiopathic pulmonary fibrosis (IPF).
- The study involved 257 IPF patients across 14 countries, comparing deupirfenidone to a placebo.
- The trial's primary focus was the change in FVC over 26 weeks.
Deupirfenidone shows promise in the fight against idiopathic pulmonary fibrosis (IPF). Results from the ELEVATE IPF trial indicate that this novel variant slowed lung function decline over 26 weeks.The trial included 257 patients across 14 countries. Deupirfenidone, a modified form of pirfenidone, demonstrated a reduced decline in forced vital capacity (FVC) compared to a placebo. This suggests it may offer significant benefits for those with IPF. The study showed the drug appears to have a more favorable adverse event profile than pirfenidone, notably with gastrointestinal symptoms, potentially improving the quality of life for patients. both 825 mg of deupirfenidone and pirfenidone delayed time to the disease progression. News Directory 3 is following the latest developments. Discover what’s next for this potential IPF treatment.
Deupirfenidone shows Promise in Treating Idiopathic Pulmonary Fibrosis
Updated May 28, 2025
A recent phase 2B trial suggests that deupirfenidone, a novel molecular variant, could offer a new approach to managing idiopathic pulmonary fibrosis (IPF). The ELEVATE IPF trial, presented at the American Thoracic Society (ATS) 2025 International Conference, explored the drug’s ability to slow the decline in lung function, as measured by forced vital capacity (FVC).
The study involved 257 IPF patients across 14 countries, comparing deupirfenidone to a placebo. Deupirfenidone is similar to pirfenidone but features deuterium, or “heavy hydrogen,” at the metabolism site. This modification, known as deuteration, aims to reduce toxicity, according to Dr. Toby Maher from the Keck School of Medicine at the University of Southern California.
The trial’s primary focus was the change in FVC over 26 weeks. Results indicated that patients receiving deupirfenidone experienced a significantly smaller decline compared to those on the placebo. Further analysis of an open-label extension showed sustained stabilization of FVC over 52 weeks in patients continuing on a high dose of deupirfenidone, suggesting a lasting treatment effect for idiopathic pulmonary fibrosis.
The multinational trial randomly assigned patients to different treatment arms,including two deupirfenidone dosages (550 mg and 825 mg),pirfenidone (801 mg),and a placebo,each administered thrice daily. The Bayesian analysis revealed a mean adjusted change in FVC of -48.4 ml for deupirfenidone patients versus -110.7 ml for the placebo group. Similarly, the adjusted mean changes in FVC% predicted were -48.4% and -1.1%, respectively.
A Frequentist inference analysis showed that the higher dose of deupirfenidone, but not the lower dose, was associated with significantly less decline in FVC and FVC% predicted compared with the placebo. Both pirfenidone and the 825 mg dose of deupirfenidone significantly delayed the time to disease progression.
Common adverse events associated with antifibrotics, such as nausea, dyspepsia, and diarrhea, were reported across all treatment arms.However, Mass General Hospital’s Dr. rachel Knipe noted that the adverse event profile of deupirfenidone appeared more favorable than that of pirfenidone, particularly regarding gastrointestinal symptoms.
maher acknowledged the presence of gastrointestinal events but emphasized the difficulty in pinpointing specific causes. He noted that variations in how investigators label side effects across different centers can complicate the interpretation of adverse events in clinical trials.
What’s next
Further research is needed to fully evaluate the long-term efficacy and safety of deupirfenidone as a potential new treatment for idiopathic pulmonary fibrosis. The initial results, though, offer hope for a more tolerable option for patients battling this challenging condition.